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C L I N I C A L R E S E A R C H A R T I C L E
Causes, Patterns, and Severity of Androgen Excess in
1205 Consecutively Recruited Women
Yasir S. Elhassan,1,2 Jan Idkowiak,1,2 Karen Smith,3 Miriam Asia,2 Helena Gleeson,2
Rachel Webster,3 Wiebke Arlt,1,2* and Michael W. O’Reilly1,2*
1Institute of Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, United
Kingdom; 2Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham
B15 2TT, United Kingdom; and 3Department of Clinical Biochemistry, University Hospitals Birmingham NHS
Foundation Trust, Birmingham B15 2GW, United Kingdom
Context: Androgen excess in women is predominantly due to underlying polycystic ovary syndrome
(PCOS). However, there is a lack of clarity regarding patterns and severity of androgen excess that
should be considered predictive of non-PCOS pathology.
Objective: We examined the diagnostic utility of simultaneous measurement of serum dehy-
droepiandrosterone sulfate (DHEAS), androstenedione (A4), and testosterone (T) to delineate
biochemical signatures and cutoffs predictive of non-PCOS disorders in women with androgen
excess.
Design: Retrospective review of all women undergoing serum androgen measurement at a large
tertiary referral center between 2012 and 2016. Serum A4 and T were measured by tandem mass
spectrometry and DHEAS by immunoassay. Patients with at least one increased serum androgen
underwent phenotyping by clinical notes review.
Results: In 1205 women, DHEAS, A4, and T were measured simultaneously. PCOS was the most
common diagnosis in premenopausal (89%) and postmenopausal women (29%). A4 was increased
in all adrenocortical carcinoma (ACC) cases (n = 15) and T in all ovarian hyperthecosis (OHT) cases (n =
7); all but one case of congenital adrenal hyperplasia (CAH; n = 18) were identified by increased
levels of A4 and/or T. In premenopausalwomen, CAHwas a prevalent cause of severeA4 (59%) andT
(43%) excess; severe DHEAS excess was predominantly due to PCOS (80%). In postmenopausal
women, all cases of severe DHEAS and A4 excess were caused by ACC and severe T excess equally by
ACC and OHT.
Conclusions: Pattern and severity of androgen excess are important predictors of non-PCOS
pathology and may be used to guide further investigations as appropriate. (J Clin Endocrinol
Metab 103: 1214–1223, 2018)
Clinical or biochemical features of androgen excess areobserved in up to 10% of women of reproductive age
(1). Androgen excess manifests clinically with hirsutism,
androgenic alopecia, acne, ovulatory dysfunction and, if
extreme and prolonged, can lead to overt and severe
masculinization (2). Recent data have also highlighted the
lifelong adverse metabolic consequences of chronic an-
drogen excess in women (3, 4). The overwhelming ma-
jority of women presenting with androgen excess have
an underlying diagnosis of polycystic ovary syndrome
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(PCOS) (5). However, complex ovarian, adrenal, and
pituitary disorders, including neoplasia, must be ex-
cluded, particularly inwomenwithmore severe androgen
excess and relatively rapid onset of symptoms (6). De-
tailed clinical history, including acuity of symptom onset,
physical examination, biochemical phenotyping, and,
where appropriate, radiological investigations are critical
in the investigation of those women deemed more likely
to harbormore sinister underlying pathology (7). However,
there is a distinct lack of data delineating severity and
patterns of androgen excess considered predictive of
non-PCOS–related disease.
Testosterone (T) and the even more potent 5a-dihy-
drotestosterone (DHT) are biologically active androgens
derived from the androgen precursors dehydroepian-
drosterone (DHEA) and androstenedione (A4). In
women, DHEA, its sulfate ester DHEAS, and its down-
stream product A4 are produced in large quantities by the
zona reticularis of the adrenal cortex (8) and activated to
potent androgens in the ovaries but importantly also
in peripheral target tissues of androgen action, such as
adipose tissue (9). Primary adrenal insufficiency is as-
sociated with severe deficiency, not only of DHEA and
A4 but also of active androgens (10, 11). Although T can
be produced in the adrenal cortex (12) and peripheral
tissues, the ovaries are a key contributor to T synthesis,
with oophorectomy leading to amajor drop in circulating
T (13). Therefore, serum T is traditionally regarded as a
biomarker of ovarian androgen production (13–15).
Conversely, DHEAS is thought to be a marker of adrenal
androgen secretion, whereas there is ongoing debate on
whether ovary or adrenals are the major source of A4.
Physiologically low circulating T in women, coupled
with the widespread use of immunoassays for its quan-
tification, limit the diagnostic utility of serum T in the
investigation of hyperandrogenism when measured in
isolation (16). Immunoassays are blighted by marked
cross-reactivity (17, 18). Liquid chromatography-tandem
mass spectrometry has emerged as a highly sensitive and
specific tool in biochemical steroid analysis, particularly
in the evaluation of very low abundance steroids such as
serum androgen concentrations in women, children, and
hypogonadal men (19, 20). We have already demon-
strated the diagnostic utility of measuring A4 alongside T
using mass spectrometry–based techniques in women
with PCOS (4). However, mass spectrometry also comes
with the capability to measure all androgens simulta-
neously in a single run, and this can create challenges
when confronted with abnormal results for analytes that
were not specifically requested.
In this study, we analyzed serum androgen data
measured in a large cohort of women consecutively
recruited in a United Kingdom secondary/tertiary
endocrine referral center over a period of 5 years. Our
aims were to gain insights into the diagnostic utility of
simultaneous measurement of serum DHEAS, A4, and T
in women with suspected androgen excess, to delineate
the biochemical signature of underlying diagnoses, and to
define serum cutoff levels that may be predictive of un-
derlying non-PCOS pathology.
Methods
Subjects and clinical protocol
We included all women who had undergone measurements
of serumDHEAS, A4, andT as part of routine clinical care at the
University Hospital Birmingham NHS Foundation Trust be-
tween 1 January 2012 and 31 December 2016. Institutional
review board approval for retrospective data review from pa-
tients undergoing routine clinical care was obtained from
University Hospital Birmingham (reference CARMS-13345).
For the purposes of analysis, we defined women younger and
older than 50 years as premenopausal and postmenopausal,
respectively, as the average age of menopause in the UK is
51 years. From the cohort of patients with simultaneous mea-
surement of serum DHEAS, A4, and T, we identified a patient
subset defined by at least one of the three serum androgens
increased above the respective local normative reference range.
This group underwent further clinical phenotyping by retro-
spective electronic case note review for age, menopausal status,
body mass index, ethnicity, clinical presentation, and the un-
derlying cause of androgen excess. The underlying diagnosis
was supported by clinical, biochemical, and radiological find-
ings in each case, with final review of the diagnosis by two
certified endocrinologists (M.W.O. and W.A.). The diagnosis of
PCOS was established according to Rotterdam criteria (1).
Serum androgen measurements
Biochemical androgen excess for each metabolite was de-
fined as a serum concentration increased above the laboratory
and age-specific normative reference range. Serum A4 and T
were analyzed by liquid chromatography-tandem mass spec-
trometry on a Prominence XR UPLC (Shimadzu Corporation)
coupled to a Triple Quad 6500 mass spectrometer (SCIEX).
Briefly, samples are analyzed by liquid/liquid extraction fol-
lowing addition of deuterated internal standards (T-d3 and
A4-d7; QMX Laboratories). Samples were separated chro-
matographically using an isocratic elution profile, ionized using
positive atmospheric pressure chemical ionization, and detected
using the following transitions: T, 289. 109 and 289. 97; T-
d3, 292. 97; A4, 287. 109 and 287. 97; and A4-d7, 294.
100. Themeasuring range for serumTwas 0.1 to 80 nmol/L and
for serum A4 0.3 to 80 nmol/L. The coefficients of variation for
T and A4 were 5.5% to 17% and 6.1% to 14%, respectively.
Serum DHEAS was analyzed using the competitive electro-
chemiluminesence immunoassay on the Cobas c702 analyzer
(Roche); the corresponding measuring range was 0.01 to
27.00 mmol/L and the coefficient of variation range 3.2%
to 5.0%.
We arbitrarily defined the severity of androgen excess as
three severity levels: mild, intermediate, and severe, separately
for premenopausal and postmenopausal women (Table 1). This
was done by prior agreement (W.A. and M.W.O.) based on
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clinical experience with knowledge of the local reference ranges
but blinded to the results of androgen measurements in the
cohort.
Statistical analysis
SPSS version 22 (SPSS Inc.) was used for descriptive data
analysis. Where relevant, data are expressed as median and first
and third quartile, unless otherwise stated. The Mann-Whitney
U test was used for comparison between two groups (pre-
menopausal and postmenopausal). Statistical significance was
set at P , 0.05.
Results
Description of the cohort and diagnostic spectrum
A total of 2269 women had at least one serum con-
centration of DHEAS, A4, or T measured during the
study period. In 1064 women (46.9%), only one or two
of the three androgens had been measured, and increased
concentrations for serum DHEAS, A4, and T were found
in 13.3%, 12.8%, and 13.0%, respectively. In 1205
women (53.1%), all three androgens had been measured
simultaneously, indicative of a higher clinical suspicion of
androgen excess (Fig. 1). The majority of these patients
were premenopausal (n = 881; 73.1%).
Overall, 378 of the 1205 women (31.4%) had in-
creased serum concentrations of one or more of DHEAS,
A4, and T and underwent clinical phenotyping, as de-
scribed in the Methods section. Of the 378 women with
androgen excess, 303 (80.2%) were premenopausal; the
median age in the premenopausal group was 29 years
compared with 62 years in the postmenopausal group
(Supplemental Table 1). The majority of women in both
groups were of Caucasian ethnicity. Although a total of
87 (28.7%) premenopausal women were of South Asian
ethnicity, only 6 (8.0%) South Asian women were
identified in the postmenopausal group. Median body
mass index (range) was 30.0 kg/m2 (16 to 65) and
32.0 kg/m2 (15 to 47) in premenopausal and post-
menopausal women, respectively.
In premenopausal women, irregular or absent men-
strual periods and clinical signs of androgen excess were
the most common causes for assessment of androgens
(47.0% and 48.0%, respectively), followed by difficulties
to conceive (5.5%). In postmenopausal women, clinical
hyperandrogenism was the most frequent cause lead-
ing to measurement of serum androgens (57.0%). Rare
causes included overt virilization (0.5% in premeno-
pausal and 7.0% in postmenopausal) and adrenal
incidentaloma (0.5% in premenopausal and 12.0% of
postmenopausal).
Although the majority of the 378 women with at least
one increased serum androgen had an underlying di-
agnosis of PCOS (77.2%), rare and very rare causes of
androgen excess were also identified, including con-
genital adrenal hyperplasia (CAH; 4.8%), adrenocor-
tical carcinoma (ACC; 4.0%), ovarian hyperthecosis
(OHT; 1.9%), Cushing disease (CD; 1.6%), adreno-
cortical adenoma (ACA; 1.3%), and ovarian tumors
(0.5%). In 36 patients (9.5%), no explanation for the
increased serum androgen concentrations was identi-
fied. PCOS was the most common diagnosis in both
premenopausal and postmenopausal women; however,
the number of PCOS diagnoses was much lower in the
postmenopausal group (29.3% vs 89.0%). Among all
women with PCOS (n = 292), 266 (91.1%) were not
taking antiandrogenic medication or metformin at the
time of biochemical assessment, 7 (2.4%) were on a
contraceptive pill, 3 (1.1%) took spironolactone, and 16
(5.4%) metformin.
The next most common diagnosis in premenopausal
women was CAH (n = 18; 6.0%), whereas in post-
menopausal women, ACC (n = 11; 14.7%) and OHT
Table 1. Severity Levels of Androgen Excess for Serum DHEAS, A4, and T
Serum Androgen Status Serum DHEAS (mmol/L) Serum A4 (nmol/L) Serum T (nmol/L)
Normal reference range
Premenopause (,50 y) 0.92–7.6 0.9–7.5 ,1.9
Postmenopause (.50 y) 0.26–5.5 0.4–2.9 ,1.9
Mild androgen excess
Premenopause (,50 y) 7.7–12.5 7.6–11.5 1.9–2.9
Postmenopause (.50 y) 5.6–12.5 3.0–7.9 1.9–2.9
Intermediate androgen excess
Premenopause (,50 y) 12.6–19.9 11.6–16.5 3.0–4.9
Postmenopause (.50 y) 12.6–19.9 8.0–12.9 3.0–4.9
Severe androgen excess
Premenopause (,50 y) $20.0 .16.5 $5.0
Postmenopause (.50 y) $20.0 $13.0 $5.0
The three levels (mild, intermediate, and severe) were arbitrarily defined, with separate cutoffs for premenopausal and postmenopausal women. Normal
reference ranges (5th to 95th centile) were defined for serum A4 and T (measured by tandemmass spectrometry) in a female local reference population
(n = 355) and for serum DHEAS (measured by immunoassay) referring to a female reference population (n = 516) provided by the manufacturer.
1216 Elhassan et al Severity and Causes of Androgen Excess in Women J Clin Endocrinol Metab, March 2018, 103(3):1214–1223
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/103/3/1214/4801236 by U
niversity of Birm
ingham
 user on 10 D
ecem
ber 2018
(n = 7; 9.3%) were most prevalent after PCOS (Fig. 1). Of
the 18 patients with CAH, 2 were newly diagnosed and
untreated at the time of androgen measurement, whereas
the remaining 16 had a previous diagnosis of CAH but
had been reviewed at our institution for either a second
opinion and advice on difficult-
to-control disease or because they
moved into the catchment area of
our hospital.
Median (range) sex hormone-
binding globulin levels (nmol/L) in
patients with PCOS, CAH, ACC, and
OHTwere 37.7 (11 to 212.2), 44.5 (21
to 131.1), 64.2 (28.8 to 270), and 60.3
(38.8 to 218.3), respectively; the cor-
responding free androgen indexes were
determined as 4.5 (0.3 to 49.6), 8.7
(1.4 to 117.9), 8.4 (0.6 to 39.2), and
10.6 (4.4 to 28.4), respectively.
Patterns of androgen excess
according to the underlying
diagnosis
In the premenopausal group, in-
creased serum DHEAS with normal
A4 and normal T was the most fre-
quent pattern observed (37.3%); an
isolated increase in A4 was the most
frequent pattern observed in the post-
menopausal cohort (41.3%) (Fig. 2A
and 2B). Mirroring this, increased
serum DHEAS was the most common constella-
tion in the premenopausal women with PCOS,
whereas isolated increased A4 was most commonly
found in postmenopausal women with PCOS (Fig. 2C
and 2D).
Figure 1. Flow chart of distribution of diagnoses according to premenopausal vs
postmenopausal status in 1205 women who underwent simultaneous measurement of
DHEAS, A4, and T. OvTu, ovarian tumor.
Figure 2. Distribution of androgen excess patterns in (A) all premenopausal women, (B) premenopausal women with underlying PCOS, (C) all
postmenopausal women, and (D) postmenopausal women with underlying PCOS. +, increased; 2, not increased.
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In the postmenopausal group, 14.8% of women had
all three serum androgens increased. This pattern was not
observed in any postmenopausal woman with a di-
agnosis of PCOS (Fig. 2B–2D) but most commonly
found in postmenopausal cases of ACC and in some
women with CAH and OHT (Fig. 3). Although A4 was
increased in all postmenopausal cases of ACC (n = 11;
Fig. 3A), there was no consistent pattern of androgen
excess in premenopausal women with ACC (n = 4;
Fig. 3A). In women with CAH, all of whom were pre-
menopausal, the combination of increased T andA4was
the most frequent pattern observed (n = 12) (Fig. 3B).
All cases of OHT, only diagnosed in postmenopausal
women, had increased serum T and in four of them in
isolation (n = 7; Fig. 3C).
Severity of androgen excess
Increased serum androgen concentrations were arbi-
trarily divided into three levels of severity (mild, in-
termediate, and severe; see Methods and Supplemental
Tables 2 and 3).
In premenopausal women, any level of DHEAS excess
was overwhelmingly caused by PCOS (Fig. 4A). CAH
was commonly found in premenopausal women with
Figure 3. Distribution of androgen excess patterns in (A) ACC, (B)
CAH, and (C) OHT. +, increased; 2, not increased; black bars,
postmenopausal; white bars, premenopausal women.
Figure 4. Severity of androgen excess according to diagnosis and
androgen measured. Three levels of androgen excess [mild (M),
intermediate (I), and severe (S)] were arbitrarily defined for each
androgen (for cutoffs, see Table 1) and are demarcated by dotted
lines. Median values for each diagnosis are denoted by a solid black
line.
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severe A4 excess (59%; intermediate, 25%; and mild,
2.5%) and T excess (43%; intermediate, 14.3%; and
mild, 5.3%). DHEAS excess in CAH was less frequent
and invariably mild (Fig. 4A–4C). There were only four
cases of ACC among the 303 premenopausal women; all
affected women showed severe androgen excess, in-
cluding one or more of the three analytes.
In postmenopausal women with PCOS, intermediate
or severe excess of any androgen was rare (Fig. 4A–4C).
Severe DHEAS excess was exclusively observed in ACC,
whereas DHEAS excess in PCOS orOHTwas rare and, if
present, only mild (Fig. 4A). Similarly, severe A4 excess
was exclusively found in ACC (Fig. 4B); mild A4 excess
was present in 68.2% of the postmenopausal PCOS
cases, but 14.2% of women with mild A4 excess were
diagnosed with ACC or OHT. Severe T excess was either
due to ACC or OHT, with a single case of PCOS
(Fig. 4C); in postmenopausal women with mild and in-
termediate T excess, we found similar numbers of cases of
ACC, OHT, and PCOS.
Causes of non-PCOS–related androgen excess even
rarer than CAH, ACC, and OHT were not reported
frequently enough to discern distinct patterns (see Sup-
plemental Tables 2 and 3 for findings in the pre-
menopausal and postmenopausal groups, respectively).
Discussion
Our study assessed simultaneously measured serum con-
centrations of the key androgen precursors DHEAS andA4
and the active androgen T in 1205 consecutively recruited
women, which represents the largest systematically
recruited androgen excess cohort reported to date and the
only to include a large subgroup of postmenopausal
women. This has enabled us to provide an age group–
specific analysis of differences in pattern and severity of
androgen excess and their relation to underlying pathologies,
with the description of distinct androgen excess signatures
that have the potential to guide further diagnostic workup.
A number of previous studies have assessed the
prevalence of androgen excess and underlying non-
PCOS pathology in cohorts of .100 women referred
to secondary care with clinical features of hyper-
androgenism (see summary of studies in Table 2)
(21–29). We identified a total of 9 studies with a median
of 318 patients (range 152 to 950). These studies
recruited overwhelmingly premenopausal women, with
several measuring serum T and DHEAS but not A4, in-
cluding the two largest studies by Azziz et al. (26) and
Carmina et al. (25) of 873 and 950 women, respectively.
The majority of these women had an underlying diagnosis
of PCOS or idiopathic hirsutism. All previous studies taken
together have collectively detected eight cases of androgen-
producing ovarian tumor, four cases of ACC, and two cases
of CD. Of note, these studies included a large proportion of
women recruited from gynecologic and reproductive en-
docrine clinics as opposed to from across the whole range
of a specialist endocrine referral center, as in our study,
which is likely to lead to the detection of greater proportion
of disorders other than PCOS.
Our study has included all patients in whom se-
rum androgen measurements were requested by any
Table 2. Summary of Previously Published Studies ThatAimed toDefine the Frequency ofDisordersObserved
in Women Who Had Serum Androgens Measured for Clinically Suspected Androgen Excess
First Author
(Reference Number)
Year of
Publication n
Menopausal
Status Setting Presentation
Di Fede (21) 2010 152 Premenopausal Endocrinology department Mild hirsutism (Ferriman–Gallwey
score 8–15)
Karrer-Voegeli (22) 2009 318 Premenopausal Endocrinology department Skin manifestations of androgen excess
Escobar-Morreale (23) 2008 270 Premenopausal Endocrinology department Oligo-/amenorrhea and/or skin
manifestations of androgen excess
Fanta (24) 2008 298 Premenopausal Obstetrics and gynecology
department
Oligo-/amenorrhea and/or skin
manifestations of androgen excess
and biochemical androgen excess
Carmina (25) 2006 950 Premenopausal Two endocrinology
departments
Skin manifestations of androgen excess
Azziz (26) 2004 873 Premenopausal Obstetrics and gynecology
reproductive endocrinology
department
Oligo-/amenorrhea and/or skin
manifestations of androgen excess
Glintborg (27) 2004 340 Premenopausal Endocrinology department Hirsutism
Unluhizarci (28) 2004 168 Premenopausal Endocrinology department Hirsutism
O’Driscoll (29) 1994 350 Premenopausal and
postmenopausal
(322 and 28 women,
respectively)
Endocrinology department Skin manifestations of androgen excess
(Continued)
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endocrinologist across a large secondary/tertiary care
specialist service during a 5-year period. This included
patients presenting with clinical features of hyper-
androgenism, but also patients assessed for suspected or
confirmed endocrine conditions that may be associated
with androgen excess, such as adrenal masses or Cushing
syndrome, resulting in higher complexity and diversity
of the underlying diagnostic spectrum. This recruitment
pattern will have contributed to a substantial number of
cases with non-PCOS–related causes of androgen excess
in our cohort, but may also have resulted in a relevant
proportion of postmenopausal women. Our recruitment
was very much reflective of the ethnic makeup of the
larger region we recruited from (30), comprising ;10%
of the United Kingdom population. The only exception
was a lower than expected number of South Asian
women in the postmenopausal age group, potentially
indicative of difficulties in accessing health care in this
group of older women who often are non-English
speaking.
Unsurprisingly, PCOSwas the most prevalent cause of
androgen excess in the premenopausal cohort and in one-
third of postmenopausal women in our study. Although
the measurement of serum T is traditionally regarded
as a sensible first-line biomarker of circulating an-
drogen burden in women (31), our data support that
simultaneousmeasurement of DHEAS andA4 alongside
T increases the sensitivity for detection of PCOS-related
androgen excess. Employing concurrent measurement
of DHEAS, A4, and T, our study demonstrated that only
49% of premenopausal and 27% of postmenopausal
women with PCOS would have been detected by iso-
lated measurement of serum T, currently recommended
as the single diagnostic androgen marker for the di-
agnosis of PCOS (32). Our findings corroborate pre-
vious reports from our group and subsequently others
that A4 is a more sensitive marker of PCOS-related
androgen excess than serum T (4, 33), which has
been recognized in the recent European position state-
ment on PCOS (31). Increased serum DHEAS concen-
trations were the most prevalent finding in the
premenopausal women with PCOS in our study, further
highlighting the well-reported significance of serum
DHEAS as a major marker of PCOS (34–36). In our
postmenopausal PCOS cases, serumA4was the primary
androgenmarker of PCOS. This shift in androgen excess
pattern at menopause may be reflective of the age-
related decline in adrenal DHEAS production, the
so-called adrenopause, which occurs alongside the
menopausal transition (37).
Importantly, we could show that the concurrent
measurement of all three androgens and subsequent
Table 2. Continued
Androgens
Measured
(Method) PCOS, n (%)
Idiopathic
Hirsutism, n (%) CAH, n (%)
Androgen-
Secreting
Tumor, n (%) Other, n (%)
DHEAS, T, and A4
(immunoassay)
72 (47.4) 77 (50.6) 3 (2.0) — —
DHEAS, T, and A4
(immunoassay)
62 (27.6) — 4 (1.8) OvTu, 2 (0.9) Idiopathic hyperandrogenism (hirsutism
or elevated androgens), 101 (44.3)
DHEAS, T, and A4
(immunoassay)
171 (63.3) 24 (8.9) 6 (2.2) — Idiopathic hyperandrogenism, 61
(22.6); hyperprolactinemia, 2 (0.7%)
DHEAS, T, and A4
(immunoassay)
290 (97.3) — 8 (2.7) — —
DHEAS and T
(immunoassay)
685 (72.1) 72 (7.6) 41 (4.3) OvTu, 2 (0.2) Idiopathic hyperandrogenism, 150 (15.8)
DHEAS and T
(immunoassay)
716 (82.0) 39 (4.7) 24 (2.2) OvTu, 2 (0.2) Hyperandrogenic insulin-resistant
acanthosis nigricans, 33 (3.1)
DHEAS and T
(immunoassay)
134 (39.4) 201 (59.1) 2 (0.6) OvTu, 1 (0.3) Prolactinoma, 1 (0.3)
CD, 1 (0.3)
DHEAS, T, and A4
(immunoassay)
96 (57.1) 27 (16.0) 12 (7.1) ACC, 3 (1.8) CD, 1 (0.6)
DHEAS, T, and A4
(immunoassay)
170 (60.0) of the 282
women who had an
ultrasound scan
— 3 (0.8) ACC, 1 (0.2) Cortisone reductase deficiency, 1 (0.2)
Two (12.0) of the 17
postmenopausal
women who were
scanned had PCOa
OvTu, 1 (0.2)
Only studies with .100 patients were included.
Abbreviation: OvTu, ovarian tumor.
aDiagnosis of PCOS in this study was based on the demonstration of polycystic ovaries on ultrasound.
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analysis of pattern and severity of androgen excess
provide important clues for the detection of ovarian and
adrenal neoplastic disease and other rare causes of
androgen excess that may require urgent diagnostic and
therapeutic management. Most frequently observed
causes of non-PCOS androgen excess were CAH and
ACC in premenopausal women and ACC and OHT in
women of postmenopausal age. CAH was the most
prevalent cause in premenopausal women, with most
patients showing combined increases in A4 and T.
Disproportionate elevations of A4 in comparison with T
in women with CAH is typically a marker of poor
disease control, and the majority of increased circulating
T in CAH is due to peripheral activation fromA4, rather
than direct adrenal overproduction (38). Although ACC
was rare in premenopausal women (1.3%), there was
a relevant number of postmenopausal ACC cases
(14.7%). Nearly all postmenopausal cases of ACC had
increased A4, and the majority had combined increases
of DHEAS, A4, and T. Only 60% of patients with ACC
had increased DHEAS, the steroid most often recom-
mended as a biochemical screen for ACC in large
adrenal tumors, adding weight to the previous recom-
mendation to always measure all three androgens in
tandem in suspected ACC (39). In postmenopausal
women, severe levels of DHEAS and A4 excess were
only observed in ACC, whereas severe T excess was
equally observed in ACC and OHT, which was the
second most common non-PCOS–related cause of an-
drogen excess in the postmenopausal age group (9.3%).
All cases of OHT had increased T, often in combination
with A4 and DHEAS, but severe excess was only ob-
served for serum T.
Previous publications in this area have almost
exclusively reported immunoassays for androgen mea-
surement, whereas current progress in androgen anal-
ysis by mass spectrometry offers the opportunity for
simultaneous multisteroid profiling. Our study used
tandem mass spectrometry for the combined highly
sensitive and specific measurement of A4 and T. The
direction of travel in clinical biochemistry is clearly
toward the development of even more wide-ranging
multisteroid profiling mass spectrometry assays, often
confronting the biochemist and clinician with increased
analytes that were not specifically requested by the
clinician but are automatically measured by the assay.
Our findings can serve as some guide for risk stratifi-
cation in the situation of incidental androgen excess
findings. In addition to the classic androgen synthesis
pathway from DHEAS via A4 to T and DHT, recent
studies have highlighted the significance of the 11-oxy-
genated androgen pathway (40, 41). This is initiated
by conversion of A4 to 11-hydroxyandrostenedione by
adrenal CYP11B1, with further downstream activation
to 11keto-testosterone and 11keto-dihydrotestosterone,
which bind and activate the androgen receptor with
similar affinity and potency as T and DHT. Our own
work and that of others has underlined the 11-oxygen-
ated androgens as the major circulating androgens in
PCOS (42) and important androgen excess parameters in
CAH (43–45). In this study, we did not measure 11-
oxygenated androgens, as the serum samples were ana-
lyzed in the routine clinical biochemistry setting where
this assay is not yet available. However, it will be very
interesting to analyze the impact of 11-oxygenated an-
drogen measurement on further delineation of condition-
specific androgen excess signatures.
A limitation of the study is in the definition of
premenopausal and postmenopausal by an age cutoff
of 50 years. However, we established the menopausal
status in the 378 women with increased androgens as
part of the clinical data extraction. Among the 303
women aged,50 years, only 2 (0.6%) had age-related
ovarian failure with increased gonadotropins. Simi-
larly, only 3 (4%) of the 75 women aged .50 years
had persistent menses. We have applied the age cutoff
of 50 years to stratify the 827 women with normal
androgen results. This enabled us to calculate the
proportions of women investigated and of those with
abnormal results (Fig. 1). Other limitations of our
study include the arbitrary definition of the severity
cutoffs and the population bias, as we recruited from a
secondary/tertiary care cohort enriched for patients
with endocrine disorders associated with androgen
excess other than PCOS, which, however, enabled
us to analyze a relevant number of cases and make
condition-specific observations on androgen excess
pattern and severity.
In conclusion, we have undertaken a detailed analysis
of a large consecutive cohort of women undergoing
serum androgen measurement for suspected androgen
excess, providing unique insights into the diagnostic
utility of combined measurement of serum DHEAS, A4,
and T concentrations. Thereby, our findings may help to
rationalize the need for further investigations such as
imaging or functional testing with dexamethasone and
gonadotropin-releasing hormone superagonists for ad-
renal and ovarian androgen suppression, respectively.
The results of this study highlight the importance of
considering patient age and the severity of biochemical
disturbances as predictors of underlying non-PCOS
pathology. In premenopausal women, severe androgen
excess should significantly increase the clinical suspicion
of non-PCOS pathology, whereas after the age of 50, even
intermediate androgen excess should prompt further
investigations.
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